Testing Brenipatide Against Placebo for Uncontrolled Asthma in Adults
Tests brenipatide at different doses against placebo in adults with moderate to severe asthma.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
Key facts
- Where
- Ajax, Hamilton, Kelowna, Montreal, Québec, Richmond, Saint-Laurent, Toronto, and Windsor, CanadaSee the 9 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07219173, who can take part
Where in Canada
- Dynamic Drug AdvancementAjax, CanadaTaking people
- St. Joseph's Healthcare HamiltonHamilton, CanadaNot yet recruiting
- Kelowna Health and Memory CentreKelowna, CanadaTaking people
- McGill University Health CentreMontreal, CanadaNot yet recruiting
- IUCPQQuébec, CanadaTaking people
- Richmond Clinical TrialsRichmond, CanadaTaking people
- C.I.C. Saint-LaurentSaint-Laurent, CanadaTaking people
- Inspiration ResearchToronto, CanadaTaking people
- Dr. Syed Anees Medicine Professional CorporationWindsor, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07219173
- Record updated
- 5 November 2026
- Original description
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma.Read full original descriptionShow less
A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Uncontrolled Moderate to Severe Asthma
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma.
Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
Inclusion: Physician-diagnosed asthma who have received a physician-prescribed asthma controller medication for at least 12 months prior to screening visit; Participants must have an asthma control questionnaire-6 (ACQ-6) score of ≥1.5 on 2 out of 3 visits before randomization; History of 1 severe asthma exacerbation that led to systemic glucocorticoid treatment in the last 12 months prior to screening visit.
Exclusion: Have a current or recent acute, active infection. For at least 30 days before screening visit and up to the randomization visit; Known pre-existing, clinically important lung condition other than asthma, including but not limited to:; chronic respiratory infection; bronchiectasis; pulmonary fibrosis; allergic bronchopulmonary aspergillosis; emphysema; chronic bronchitis; eosinophilic granulomatosis with polyangiitis; chronic obstructive pulmonary disease, and; other mimics of asthma, that is, vocal cord dysfunction; Participants are excluded from the study if any of the following criteria apply:; An established diagnosis of occupational asthma.